Get the Stockscreener App
1.93
0.52%
-0.01
After Hours:
1.91
-0.02
-1.04%
Immutep Limited Adr stock is traded at $1.93, with a volume of 55,713.
It is down -0.52% in the last 24 hours and down -9.39% over the past month.
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
See More
Previous Close:
$1.94
Open:
$1.93
24h Volume:
55,713
Relative Volume:
0.49
Market Cap:
$280.73M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-8.5892
EPS:
-0.2247
Net Cash Flow:
-
1W Performance:
-3.98%
1M Performance:
-9.39%
6M Performance:
-3.50%
1Y Performance:
-19.92%
1-Day Range:
$1.91
$1.95
1-Week Range:
$1.90
$2.05
52-Week Range:
$1.66
$3.335
Immutep Limited Adr Stock (IMMP) Company Profile
Compare IMMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
1.93 | 280.73M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-17-24 | Initiated | CapitalOne | Overweight |
| Aug-03-23 | Initiated | Robert W. Baird | Outperform |
| Aug-03-21 | Initiated | Ladenburg Thalmann | Buy |
| Jul-16-21 | Resumed | Maxim Group | Buy |
| Sep-28-18 | Initiated | B. Riley FBR | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
View All
Immutep Limited Adr Stock (IMMP) Latest News
Immutep Limited (NASDAQ:IMMP) Shares Sold by Jane Street Group LLC - Defense World
Verition Fund Management LLC Has $57,000 Stock Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - The Manila Times
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewswire Inc.
Immutep shares new cancer study results - Investing.com
Immutep Quarterly Activities Report Q1 FY25 - GlobeNewswire
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial - The Manila Times
Immutep Limited ADR (IMMP) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Metric Deep Dive: Understanding Immutep Limited ADR (IMMP) Through its Ratios - The Dwinnex
Immutep reports positive results in cancer study - Investing.com
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September - Benzinga
Research Analysts Issue Forecasts for Immutep Limited’s FY2025 Earnings (NASDAQ:IMMP) - Defense World
Immutep Limited ADR (IMMP) Stock: Navigating a Year of Volatility - The InvestChronicle
Short Interest in Immutep Limited (NASDAQ:IMMP) Declines By 10.1% - Defense World
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody - GlobeNewswire
Virtu Financial LLC Buys 32,864 Shares of Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep reports steady progress in Q4 FY24 - Investing.com India
Immutep reports steady progress in Q4 FY24 By Investing.com - Investing.com Australia
Immutep Limited (NASDAQ:IMMP) Shares Acquired by BNP Paribas Financial Markets - Defense World
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer - GlobeNewswire
Guess which ASX healthcare stock is surging on big FDA news - The Motley Fool
Why 29Metals, Immutep, Insignia, and Perenti shares are pushing higher today - The Motley Fool
FY2027 EPS Estimates for Immutep Limited (NASDAQ:IMMP) Cut by Capital One Financial - American Banking and Market News
Equities Analysts Set Expectations for Immutep Limited’s FY2029 Earnings (NASDAQ:IMMP) - American Banking and Market News
Immutep Limited (NASDAQ:IMMP) Short Interest Up 6.2% in June - American Banking and Market News
Immutep Receives Regulatory Clearance for Phase I Study of - GlobeNewswire
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Stocks of the Hour: Adherium, Nanoveu, Nimy Resources - ShareCafe
Immutep appoints research institute to conduct first-in-human study of IMP761 - Biotech Dispatch
10 Best Australian Stocks To Buy - Yahoo Finance
Immutep LimitedADR (IMMP) Price Target Increased by 7.83% to 2.80 - MSN
Immutep Announces GMP Manufacturing Process Developed for - GlobeNewswire
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Immutep Ltd (IMMP) Stock Price, Trades & News - GuruFocus.com
Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO - Yahoo Finance
Immutep Limited Adr Stock (IMMP) Financials Data
There is no financial data for Immutep Limited Adr (IMMP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):